NasdaqGS - Nasdaq Real Time Price USD

Shattuck Labs, Inc. (STTK)

Compare

0.9499

+0.0436

+(4.81%)

At close: April 11 at 4:00:01 PM EDT

0.9067

-0.04

(-4.55%)

After hours: April 11 at 7:19:48 PM EDT

3 Promising Penny Stocks With Market Caps Under $300M

Amid ongoing market volatility and tariff uncertainties, the S&P 500 and Dow Jones Industrial Average have experienced significant declines, while the Nasdaq Composite showed a slight increase. For investors willing to explore beyond well-known companies, penny stocks—often associated with smaller or newer enterprises—can present unexpected opportunities. Despite their somewhat outdated label, these stocks remain relevant for those seeking potential growth driven by solid financial health.

Simply Wall St. 3 days ago

TUSK

AIRJ

AIRJW
Shattuck Labs Announces Participation in Upcoming 24th Annual Needham Virtual Healthcare Conference

AUSTIN, TX and DURHAM, NC, April 02, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors for the treatment of patients with inflammatory and immune-related diseases, today announced that company management will present at and participate in one-on-one meetings at the 24th Annual Needham Virtual Healthcare Conference, taking place April 7–10, 202

GlobeNewswire 9 days ago

STTK
+4.81%
Shattuck Labs Full Year 2024 Earnings: Misses Expectations

Shattuck Labs ( NASDAQ:STTK ) Full Year 2024 Results Key Financial Results Net loss: US$75.4m (loss narrowed by 14...

Simply Wall St. 14 days ago

STTK
+4.81%
Shattuck Labs Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Highlights

– Presented preclinical non-human primate (NHP) data at the 20th Congress of European Crohn’s and Colitis Organization in Inflammatory Bowel Diseases 2025 (ECCO) for SL-325, a potentially first-in-class blocking antibody to DR3, the receptor for TL1A; data demonstrated favorable safety profile, full receptor occupancy, lack of DR3 agonism – – SL-325 advances toward Phase 1; on track for IND filing in the third quarter of 2025 – – Cash balance of approximately $73.0 million as of December 31, 202

GlobeNewswire 15 days ago

STTK
+4.81%
Favourable Signals For Shattuck Labs: Numerous Insiders Acquired Stock

Usually, when one insider buys stock, it might not be a monumental event. But when multiple insiders are buying like...

Simply Wall St. last month

STTK
+4.81%
Shattuck Labs Announces Positive Data from the Preclinical GLP Toxicology Study of SL-325 at the 20th Congress of European Crohn’s and Colitis Organization (ECCO) in Inflammatory Bowel Diseases 2025

– SL-325 is a high-affinity DR3 blocking antibody being developed for the treatment of inflammatory bowel disease (IBD); No evidence of toxicity or residual agonism observed in non-human primate toxicology study – – SL-325 receptor occupancy (RO) and pharmacokinetic (PK) profile observed suggestive of extended dosing intervals; IND filing expected in the third quarter of 2025 – AUSTIN, TX & DURHAM, NC, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a biotechnolo

GlobeNewswire last month

STTK
+4.81%
Shattuck Labs Announces Oral Presentation at Upcoming 20th Congress of European Crohn’s and Colitis Organization (ECCO) in Inflammatory Bowel Diseases 2025

AUSTIN, TX & DURHAM, NC, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors for the treatment of patients with inflammatory and immune-related diseases, today announced an upcoming oral presentation at the 20th Congress of ECCO in Inflammatory Bowel Diseases 2025 being held in Berlin, Germany from February 19–22, 2025. This presentatio

GlobeNewswire last month

STTK
+4.81%
Shattuck Labs Announces Poster Presentation at Upcoming 2025 Crohn’s and Colitis Congress

AUSTIN, TX and DURHAM, NC, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors for the treatment of patients with inflammatory and immune-related diseases, today announced an upcoming poster presentation at the 2025 Crohn’s and Colitis Congress being held in San Francisco, California from February 6–8, 2025. Presentation DetailsFormat:

GlobeNewswire 2 months ago

STTK
+4.81%
Planet Image International Leads 3 US Penny Stocks To Consider

As the Federal Reserve holds interest rates steady, the U.S. stock market has seen fluctuations, with major indices experiencing both gains and losses amid ongoing earnings reports from big tech companies. For investors looking beyond these large-cap stocks, penny stocks—often representing smaller or newer companies—remain a relevant area of interest despite their somewhat outdated label. These stocks can offer a blend of affordability and growth potential, especially when backed by robust...

Simply Wall St. 2 months ago

YSG

YIBO

STTK
+4.81%
Shattuck Labs Announces Presentation at the 43rd Annual J.P. Morgan Healthcare Conference

AUSTIN, TX and DURHAM, NC, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors for the treatment of patients with inflammatory and immune-related diseases, today announced that company management will present a corporate update and participate in one-on-one meetings at the 43rd Annual J.P. Morgan Healthcare Conference being held in San

GlobeNewswire 3 months ago

STTK
+4.81%
Shattuck Labs highlights upcoming key milestones in 2025

Shattuck Labs (STTK) announced a corporate update and highlighted upcoming key milestones anticipated in 2025. “We have made considerable progress in the development of our potential first-in-class DR3 blocking antibody, SL-325,” said Taylor Schreiber, M.D., Ph.D., CEO of Shattuck. “Based on observations from our preclinical, non-human primate (NHP) studies, we remain highly optimistic that SL-325 will achieve a more complete blockade of the clinically validated DR3/TL1A signaling pathway and ar

TipRanks 3 months ago

STTK
+4.81%
Shattuck Labs Provides Corporate Update and Highlights Upcoming Key Milestones in 2025

AUSTIN, TX and DURHAM, NC, Jan. 02, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors for the treatment of patients with inflammatory and immune-related diseases, today announced a corporate update and highlighted upcoming key milestones anticipated in 2025. “We have made considerable progress in the development of our potential first-in-class

GlobeNewswire 3 months ago

STTK
+4.81%
Barfresh Food Group And 2 Other US Penny Stocks To Consider

As the U.S. stock market navigates a mix of rising Treasury yields and fluctuating indices, investors are keenly observing opportunities for growth amid these dynamic conditions. Penny stocks, while often overlooked, remain an intriguing segment of the market. These stocks typically represent smaller or newer companies and can offer significant growth potential when supported by strong financial health and fundamentals.

Simply Wall St. 3 months ago

STTK
+4.81%
BRFH

FKWL
Shattuck Labs Announces Participation in Upcoming December Conferences

AUSTIN, TX and DURHAM, NC, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors for the treatment of patients with cancer and chronic immune-related diseases, today announced that company management will participate in two investor conferences in December 2024. Presentation DetailsConference: Piper Sandler 36th Annual Healthcare Conferen

GlobeNewswire 4 months ago

STTK
+4.81%
Shattuck Labs Third Quarter 2024 Earnings: Beats Expectations

Shattuck Labs ( NASDAQ:STTK ) Third Quarter 2024 Results Key Financial Results Net loss: US$16.7m (loss narrowed by 40...

Simply Wall St. 4 months ago

STTK
+4.81%
Shattuck Labs sees cash runway into 2027

Shattuck has effectuated its restructuring plan to prioritize the development of the DR3 program and align the Company’s cost and workforce structure with the its current goals and clinical development strategy. The Company has substantially completed the reduction in force associated with the discontinuation of SL-172154. Shattuck believes its cash and cash equivalents and investments will be sufficient to fund its planned operations into 2027, beyond results from its Phase 1 clinical trial of

TipRanks 4 months ago

STTK
+4.81%
Shattuck Labs Reports Third Quarter 2024 Financial Results and Recent Business Highlights

– Announced development of SL-325, a first-in-class antagonist antibody to DR3, the receptor for TL1A; IND filing expected in Q3'2025 – – Cash balance of approximately $90M as of September 30, 2024; expected to fund operations into 2027 – AUSTIN, TX and DURHAM, NC, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (Nasdaq: STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors for the treatment of

GlobeNewswire 4 months ago

STTK
+4.81%
Down -64.19% in 4 Weeks, Here's Why Shattuck Labs (STTK) Looks Ripe for a Turnaround

Shattuck Labs (STTK) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Zacks 5 months ago

STTK
+4.81%
After Plunging -68.96% in 4 Weeks, Here's Why the Trend Might Reverse for Shattuck Labs (STTK)

The heavy selling pressure might have exhausted for Shattuck Labs (STTK) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Zacks 5 months ago

STTK
+4.81%
Top Midday Decliners

Top Midday Decliners

PREMIUM
MT Newswires 6 months ago

STTK
+4.81%
EGRX

Performance Overview

Return	STTK	S&P 500 (^GSPC)
YTD	-21.50%	-8.81%
1-Year	-90.12%	+3.16%
3-Year	-75.00%	+21.55%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Shattuck Labs, Inc. (STTK)

3 Promising Penny Stocks With Market Caps Under $300M

Shattuck Labs Announces Participation in Upcoming 24th Annual Needham Virtual Healthcare Conference

Shattuck Labs Full Year 2024 Earnings: Misses Expectations

Shattuck Labs Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Highlights

Favourable Signals For Shattuck Labs: Numerous Insiders Acquired Stock

Shattuck Labs Announces Positive Data from the Preclinical GLP Toxicology Study of SL-325 at the 20th Congress of European Crohn’s and Colitis Organization (ECCO) in Inflammatory Bowel Diseases 2025

Shattuck Labs Announces Oral Presentation at Upcoming 20th Congress of European Crohn’s and Colitis Organization (ECCO) in Inflammatory Bowel Diseases 2025

Shattuck Labs Announces Poster Presentation at Upcoming 2025 Crohn’s and Colitis Congress

Planet Image International Leads 3 US Penny Stocks To Consider

Shattuck Labs Announces Presentation at the 43rd Annual J.P. Morgan Healthcare Conference

Shattuck Labs highlights upcoming key milestones in 2025

Shattuck Labs Provides Corporate Update and Highlights Upcoming Key Milestones in 2025

Barfresh Food Group And 2 Other US Penny Stocks To Consider

Shattuck Labs Announces Participation in Upcoming December Conferences

Shattuck Labs Third Quarter 2024 Earnings: Beats Expectations

Shattuck Labs sees cash runway into 2027

Shattuck Labs Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Down -64.19% in 4 Weeks, Here's Why Shattuck Labs (STTK) Looks Ripe for a Turnaround

After Plunging -68.96% in 4 Weeks, Here's Why the Trend Might Reverse for Shattuck Labs (STTK)

Top Midday Decliners

Performance Overview